electroCore, Inc. (NASDAQ:ECOR – Get Free Report) CFO Joshua Lev sold 3,000 shares of electroCore stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $9.36, for a total value of $28,080.00. Following the transaction, the chief financial officer owned 84,889 shares in the company, valued at $794,561.04. This trade represents a 3.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
electroCore Stock Down 6.2%
electroCore stock opened at $9.71 on Friday. The stock has a market capitalization of $87.58 million, a PE ratio of -5.85 and a beta of 0.92. electroCore, Inc. has a twelve month low of $4.41 and a twelve month high of $10.95. The company has a 50 day moving average of $7.81 and a 200-day moving average of $7.30.
electroCore (NASDAQ:ECOR – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.09. The company had revenue of $9.45 million for the quarter, compared to analyst estimates of $9.49 million. electroCore had a negative return on equity of 1,956.38% and a negative net margin of 39.96%. Equities analysts anticipate that electroCore, Inc. will post -1.4 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of electroCore in a research note on Wednesday, June 24th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, electroCore has a consensus rating of “Hold” and an average price target of $18.00.
Check Out Our Latest Report on ECOR
About electroCore
electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.
The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.
Read More
- Five stocks we like better than electroCore
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
